Orris

Therapeutics 2 : synopsis 1. Basic principles of cancer chemotherapeutic agents 2. General introduction of cancer chemotherapeutic agents ( classification, basic moa , indications and common adrs ) 3. Chemo induced nausea and vomiting 4. Management of breast cancer and leukaemia

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Here's your complete Therapeutics 2 Synopsis covering all four requested topics. Here's a quick orientation guide:

What's Covered

Section 1 — Basic Principles

  • Goals of treatment (cure → control → palliation)
  • Types of chemo by timing (adjuvant, neoadjuvant, maintenance, palliative)
  • Cell cycle specificity (CCS vs CCNS) with diagram
  • Combination chemotherapy rationale
  • Drug resistance mechanisms (P-glycoprotein, MDR)
  • General ADRs and cytoprotectants (leucovorin, mesna, G-CSF)

Section 2 — Drug Classification (7 Classes)

Each class includes: MOA, key drugs, indications, and notable ADRs
  1. Antimetabolites (methotrexate, 5-FU, cytarabine, 6-MP…) — S-phase specific
  2. Alkylating agents (cyclophosphamide, cisplatin, busulfan…) — CCNS
  3. Topoisomerase inhibitors (doxorubicin, etoposide, irinotecan…)
  4. Microtubule inhibitors — vincas (vincristine) + taxanes (paclitaxel)
  5. Antitumour antibiotics (bleomycin, dactinomycin)
  6. Hormonal agents (tamoxifen, AIs, GnRH agonists, fulvestrant)
  7. Targeted/biological (TKIs, monoclonal antibodies, checkpoint inhibitors)

Section 3 — CINV

  • 4 types (acute, delayed, anticipatory, refractory)
  • Emetogenic risk levels with drug examples
  • 6 antiemetic drug classes with doses, MOA, ADRs
  • Management algorithm for HEC, MEC, and refractory CINV

Section 4 — Breast Cancer & Leukaemia

  • Breast cancer by subtype: ER+, HER2+, TNBC — with specific regimens
  • ALL: Induction (VPDL), CNS prophylaxis, maintenance, Ph+ considerations
  • AML: 7+3 regimen, FLT3/IDH targeted therapy, APL (ATRA + ATO)
  • CLL: Ibrutinib, venetoclax, FCR
  • CML: TKI generations (imatinib → ponatinib), BCR-ABL monitoring
This is a shared conversation. Sign in to Orris to start your own chat.